| __timestamp | Catalyst Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 8185000 |
| Thursday, January 1, 2015 | 8597010 | 8871000 |
| Friday, January 1, 2016 | 7910260 | 9645000 |
| Sunday, January 1, 2017 | 7304399 | 12387000 |
| Monday, January 1, 2018 | 15875961 | 14381000 |
| Tuesday, January 1, 2019 | 36881187 | 19238000 |
| Wednesday, January 1, 2020 | 44233754 | 17425000 |
| Friday, January 1, 2021 | 49628000 | 23040000 |
| Saturday, January 1, 2022 | 58183000 | 25116000 |
| Sunday, January 1, 2023 | 133710000 | 51953000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, Catalyst Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Catalyst Pharmaceuticals saw a staggering 2,887% increase in SG&A expenses, peaking in 2023. In contrast, CymaBay Therapeutics maintained a more conservative growth of 535% over the same period.
Catalyst's aggressive spending strategy, particularly evident in the 2023 fiscal year, suggests a focus on expansion and market penetration. Meanwhile, CymaBay's steadier approach may reflect a strategy centered on sustainable growth and cost efficiency. As these companies continue to evolve, their SG&A management will remain a key indicator of their strategic priorities and financial health.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs Catalyst Pharmaceuticals, Inc.
GSK plc vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Catalent, Inc. and CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and Perrigo Company plc
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights